Money Mediary – Weekly Recap March 28th

This Week's Top Insider Moves That Matter

If there’s a word for this week, it’s conviction. Executives and institutional players didn’t just dip their toes in or trim their positions—some did cannonballs. On the sell side, we saw a $74.6M liquidation in biotech, a rare double-tap from an energy CEO moving over $55M out the door, and SoftBank quietly unloading millions in Lemonade $LMND ( ▲ 0.51% ) , perhaps accepting that not all fintech dreams have staying power.

Meanwhile, the buys were bolder than usual. The Column Group dropped nearly $12M into a preclinical biotech name trading under $12—a 10% stake kind of move. A familiar name in James Monroe III, director of Globalstar $GSAT ( ▲ 0.31% ) , made a nearly $5M bet that could signal long-range optimism for the satellite comms space. And finally, Frost at OPKO Health is back again—because what’s a week in insider buys without Dr. Frost adding a few hundred thousand shares?

Let’s break it down.

Biggest Insider Sales

⚡️ StandardAero Inc. $SARO ( ▲ 0.84% ) – $180M from Singapore

• Who’s Selling? GIC Private Ltd (10% Owner)

• What They Sold: 6.63M shares at $27.16

• Total Value: $180M

• Why It Matters: When a sovereign wealth fund moves this kind of volume, it's never casual. Could signal portfolio reshuffling or macro exposure concerns.
  

🔥 Southwest Gas Holdings $SWX ( ▼ 0.93% ) – Icahn Pulls $156M

• Who’s Selling? Carl Icahn (10% Owner)

• What He Sold: 2.1M shares at $74.60

• Total Value: $156.6M

• Why It Matters: The activist legend trims a major energy utility stake after years of drama. A cooling off or capital redeployment?
  

🔌 Broadcom $AVGO ( ▲ 2.21% ) – Director Cashes Out $120.6M

• Who’s Selling? Henry Samueli (Director)

• What He Sold: 663,976 shares at $181.60

• Total Value: $120.6M

• Why It Matters: AVGO is a juggernaut, but this magnitude of selling isn’t common. Keep an eye on institutional follow-through.
  

🧠 Compass Therapeutics $COMP ( ▲ 0.14% ) – $91.5M Exit by SoftBank

• Who’s Selling? SVF Excalibur (Cayman) Ltd (10% Owner)

• What They Sold: 10M shares at $9.15

• Total Value: $91.5M

• Why It Matters: More trimming from SoftBank across growth/biotech names. Possibly repositioning ahead of macro headwinds?
  

🧬 Solenis Therapeutics $SLNO ( ▼ 1.31% ) – $74.6M Biotech Rebalance

• Who’s Selling? Vivo Opportunity, LLC (10% Owner)

• What They Sold: 1.1M shares at $67.80

• Total Value: $74.6M

• Why It Matters: The scale suggests strategy, not panic. Still, the timing near recent highs may hint at overvaluation.

Biggest Insider Buys

💼 Corebridge Financial $CRBG ( ▲ 0.1% ) – $40M Reinvestment

• Who’s Buying? Corebridge Financial, Inc.

• What They Bought: 1.6M shares at $25.00

• Total Investment: $40M

• Why It Matters: A significant reinvestment by the firm itself. Could indicate undervaluation or a balance sheet move pre-earnings.
  

🛡️ Prudential Financial $PRU ( ▼ 1.09% ) – $38.3M Confidence Buy

• Who’s Buying? Prudential Insurance Co. of America (10% Owner)

• What They Bought: 1.34M shares at $28.53

• Total Investment: $38.25M

• Why It Matters: When a major insurer bulks up on a peer, it’s worth noting. A sector-level bet with teeth.
  

🧬 Sarepta Therapeutics $SRZN ( ▲ 0.29% ) – $12M Deep Biotech Bet

• Who’s Buying? Column Group III GP, LP (10% Owner)
  What They Bought: 1.03M shares at $11.60

• Total Investment: $12M

• Why It Matters: Private equity doubling down in biotech usually means they know something others don’t—yet.
  

🧪 Benitec Biopharma $BNTC ( ▼ 2.2% ) – $11.7M from Suvretta

• Who’s Buying? Suvretta Capital Management (Director)

• What They Bought: 900K shares at $13.00

• Total Investment: $11.7M

• Why It Matters: Hedge fund money entering early-stage biotech.
  

🔬 Exicure Inc. $XCUR ( ▼ 3.01% ) – $8.7M from HiTron Systems

• Who’s Buying? HiTron Systems Inc. (10% Owner)

• What They Bought: 2.9M shares at $3.00

• Total Investment: $8.7M

• Why It Matters: This volume at low prices shows strategic accumulation. Could precede a merger, licensing deal, or turnaround.

🔬Insider Under the Microscope: Broadcom

This week, Broadcom $AVGO ( ▲ 2.21% ) saw one of the most substantial insider sales we’ve tracked—just as the stock dropped 11.76% over a five-day span.

Henry Samueli, Director and co-founder, sold 663,976 shares at an average price of $181.60, totaling approximately $120.6 million. That ranks among the largest insider sales across the entire S&P 500 this week.

The timing is notable. Broadcom shares have surged over the past year on the back of strong AI infrastructure demand, but this week saw sharp selling across the semiconductor space.

Peers like NVIDIA (-6.82%), AMD (-3.02%), and Micron (-4.69%) all turned red, suggesting broader sector weakness—likely influenced by shifting macro expectations and rising yields.

At this point, it’s unclear whether Samueli’s sale reflects a personal liquidity event, portfolio diversification, or a shift in his long-term outlook. 

It’s worth noting that no additional insider sales from other Broadcom executives were filed this week, based on available data.

While insider sales are not inherently bearish, the size of this one stands out. 

It comes at a time when semiconductor valuations remain elevated and investor sentiment appears to be cooling—at least temporarily.

There’s no reason to jump to conclusions, but it’s a move worth flagging.